Shares are being absorbed by patient and savvy investors. This is typical in any storied OTC equity that runs 10,000% over the course of several months. The most storied pharmas discussed here traded very similar patterns. Those who truly conduct due diligence can grasp the potential here and are positioning as such. Traders can bring liquity and new eyes to the arena, so the market, especially the OTC needs all types. Plenty of patience here to watch this mature.
Looking forward to 10-K, 10-Q. Not expecting much other than hopefully seeing further evidence of institutional and insiders lining up behind equity positions here and further eliminating debts and warrants overhanging. I think they can be positioned to eliminate all potential conversions and not need to utilize the entire 2B authorized. Big difference in stock price if they can keep share structure closer to 1 bil versus needing 2 bil or more to execute on their pipeline. Plus filings up to date will confirm to many a solid foundation going forward, so would be a catalyst to some investors.
I think we see this continually strengthen, with consolidation days mixed in until we hear more about pipeline progress. The OSA program has some investment lined up, and presumably doing preclinical work on new formulations. Any details regarding progress with OSA would be a catalyst. IMO, the bigger catalysts is their dealings with NIH and having KRM-ll-81 make it to final stages (tier 3) of their robust preclincal process. Researching all the extensive preclinical efforts with this candidate drug AND the success thus far for BOTH epilepsy and pain indications, I can forsee multiple BP deals come from this effort. These would be absolutely huge and dwarf past storied stocks. Obvious risk in any drug development, but as longs here can attest, the potential is flat out amazing. Reading all the filings too, you can see insiders, etc positioning for success. Nothing is guaranteed, but risk v reward is why speculative money is here on the OTC. GLTA.
